Lydecken K
Schweiz Arch Neurol Neurochir Psychiatr. 1977;120(1):75-82.
The sustained release form of butyrophenone derivative moperone hydrochloride was tested within the scope of an open clinical study including 20 patients with mostly chronic, schizophrenic psychoses. Five patients were prematurely dropped from the trial for various reasons. Generally speaking, marked improvement was observed for the remaining 15 patients after the five-week test period as compared to previous neuroleptic medication. Three patients exhibited extrapyramidal reactions; no other side effects were observed. Gastric tolerance of the tablets was very good.
在一项开放性临床研究范围内，对丁酰苯衍生物盐酸莫哌隆的缓释剂型进行了测试，该研究纳入了20例大多患有慢性精神分裂症的患者。5例患者因各种原因提前退出试验。总体而言，与之前使用的抗精神病药物相比，在为期五周的测试期后，其余15例患者有明显改善。3例患者出现锥体外系反应；未观察到其他副作用。片剂的胃耐受性非常好。
